Prostate Cancer International is
for 2011 by Great NonProfits
The “New” Prostate Cancer InfoLink is delighted to see Dr. Pazdur and colleagues from the U.S. Food & Drug Administration (FDA) present their reasoning for non-approval of the 5α-reductase inhibitors (5-ARIs) dutasteride and finasteride for prevention of prostate cancer in a new article in the New England Journal of Medicine.
Filed under: Diagnosis, Living with Prostate Cancer, Prevention, Risk | Tagged: 5-ARI, 5α-reductase inhibitor, FDA, Prevention | 11 Comments »
Yesterday the US Food & Drug Administration (FDA) updated its guidance on the use of 5α-reductase inhibitors with specific reference to the risk that use of these products may be able to induce high-grade (and therefore high-risk) prostate cancer in a small subset of men treated with these agents.
Filed under: Diagnosis, Prevention, Risk | Tagged: 5-ARI, dutasteride, FDA, finasteride, Prevention, risk | 4 Comments »
Over the years, a variety of studies have demonstrated a possible impact of aspirin and other non-steroidal anti-inflammatory agents or NSAIDs (e.g., ibuprofen, COX-2 inhibitors) on risk for prostate cancer. (See, for example, this report from late in 2010.)
Filed under: Diagnosis, Drugs in development, Prevention, Risk | Tagged: acetaminophen, Prevention, risk | 3 Comments »
It is becoming increasingly clear that the prevention, treatment, and management of prostate cancer is at an intellectual as well as a practical, clinical crossroads.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: dutasteride, finasteride, Prevention, PSA, screening, supplement, testing, testosterone | 2 Comments »
A new Canadian study just reported in the Journal of Clinical Oncology has failed to find any significant benefit from the use of vitamin E, selenium, and soy protein supplements in the prevention of prostate cancer.
Filed under: Diagnosis, Prevention, Risk | Tagged: HG-PIN, high-grade, Prevention, prostatic intraepithelial neoplasia, risk, selenium, soy, vitamin E | 5 Comments »
Out of the 600+ presentations at the IMPaCT meeting in Orlando last week, your correspondent somehow managed to overlook an interesting poster that offers new evidence in support of the potential benefit of statin therapy in the prevention and management of prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Prevention, progression, statin, trial | 2 Comments »
Many men use vitamins and other supplements to prevent the onset of prostate cancer or to prevent the progression of prostate cancer after diagnosis. However, a new article in Family Practice suggests that there is no really good clinical evidence for either of these practices in the published literature.
Filed under: Living with Prostate Cancer, Management, Prevention | Tagged: outcome, Prevention, risk, supplement, vitamin | Leave a Comment »
A recent article in the Journal of General Internal Medicine argues that using 5α-reductase (5-ARI) therapy (i.e., with dutasteride or finasteride) to prevent the early onset of prostate cancer is not justified by the available data. … And we entirely agree,
Filed under: Diagnosis, Prevention, Risk | Tagged: 5-ARI, dutasteride, finasteride, outcome, pomegranate, Prevention | 2 Comments »
Nearly a year ago now we reported data from one relatively large study that suggested there was no direct connection between intake of vitamin D (in its 25-hydroxy vitamin D formulation) and risk for prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: Prevention, risk, vitamin D | 3 Comments »
Based on the 14 to 2 “against” vote of an Oncology Drugs Advisory Committee meeting late last year, the U.S. Food & Drug Administration has rejected the application to approve dutasteride (Avodart) for prevention of prostate cancer in men at potentially elevated risk for a future postive biopsy.
Filed under: Drugs in development, Prevention | Tagged: dutasteride, FDA, Prevention | 5 Comments »
There are new data showing that the antidepressant escitalopram (Lexapro/Forest) — a selective serotonin re-uptake inhibitor or SSRI — can significantly reduce hot flashes among women undergoing menopause. If that is the case, one wonders whether drugs of this class might have a similar impact on hot flashes in men on androgen deprivation therapy (ADT).
Filed under: Living with Prostate Cancer, Management | Tagged: hot flashes, Management, Prevention, SSRIs | 2 Comments »
The full text of a review entitled “Fruit and vegetables and cancer risk” is available on the web site of the British Journal of Cancer, and it is not good news.
Filed under: Diagnosis, Prevention, Risk | Tagged: cancer, fruit, Prevention, risk, vegetable | 3 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site